Study: 38% of FDA Advisory Meetings Included a Patient or Consumer Rep Tied to a Pharma-Funded Group
Patient and consumer representatives are supposed to bring the public's voice into FDA drug reviews. A new USC analysis finds that in more than 1 in 10 advisory meetings, one of them was affiliated with a group funded by the very company whose drug was on the table.
The FDA Promises a Custom-Fit Rulebook for Rare Disease Drugs. Patients Should Read the Fine Print.
The FDA’s new Rare Disease Framework Initiative promises evidence standards tailored to tiny patient populations. What it covers, how to weigh in on October 28, and the questions it leaves open.